JP2020530437A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530437A5 JP2020530437A5 JP2019570982A JP2019570982A JP2020530437A5 JP 2020530437 A5 JP2020530437 A5 JP 2020530437A5 JP 2019570982 A JP2019570982 A JP 2019570982A JP 2019570982 A JP2019570982 A JP 2019570982A JP 2020530437 A5 JP2020530437 A5 JP 2020530437A5
- Authority
- JP
- Japan
- Prior art keywords
- neopeptides
- recombinant poxvirus
- neopeptide
- tumor
- poxvirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023100296A JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305760 | 2017-06-21 | ||
| EP17305760.5 | 2017-06-21 | ||
| EP18305496 | 2018-04-23 | ||
| EP18305496.4 | 2018-04-23 | ||
| PCT/EP2018/066668 WO2018234506A2 (en) | 2017-06-21 | 2018-06-21 | PERSONALIZED VACCINE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100296A Division JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530437A JP2020530437A (ja) | 2020-10-22 |
| JP2020530437A5 true JP2020530437A5 (https=) | 2023-07-05 |
| JP7334124B2 JP7334124B2 (ja) | 2023-08-28 |
Family
ID=62599637
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570982A Active JP7334124B2 (ja) | 2017-06-21 | 2018-06-21 | 個別化ワクチン |
| JP2023100296A Pending JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A Pending JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100296A Pending JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A Pending JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11969462B2 (https=) |
| EP (1) | EP3641803A2 (https=) |
| JP (3) | JP7334124B2 (https=) |
| KR (2) | KR20240113607A (https=) |
| CN (1) | CN111065406A (https=) |
| AU (1) | AU2018287159B2 (https=) |
| CA (1) | CA3067405A1 (https=) |
| IL (1) | IL271558B2 (https=) |
| SG (1) | SG11201912429RA (https=) |
| WO (1) | WO2018234506A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220349010A1 (en) | 2018-07-26 | 2022-11-03 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| WO2020141207A1 (en) * | 2019-01-03 | 2020-07-09 | Evaxion Biotech Aps | Vaccines targeting neoepitopes |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020176797A1 (en) * | 2019-02-27 | 2020-09-03 | Nektar Therapeutics | Immunotherapeutic combination for treating cancer |
| PH12022550240A1 (en) * | 2019-08-29 | 2022-12-19 | Astellas Pharma Inc | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
| EP3842065A1 (en) * | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| US20230097513A1 (en) * | 2020-02-03 | 2023-03-30 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| CN111303277A (zh) * | 2020-02-19 | 2020-06-19 | 中国人民解放军军事科学院军事医学研究院 | 一种抗天花病毒免疫球蛋白F(ab′)2及其制备方法 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2023209068A1 (en) | 2022-04-28 | 2023-11-02 | Carbocalyx Gmbh | Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments |
| WO2024062098A1 (en) | 2022-09-23 | 2024-03-28 | Transgene | Recombinant pseudocowpox virus encoding an interleukin-12 |
| CN115927215B (zh) * | 2023-01-18 | 2025-10-17 | 中国医学科学院病原生物学研究所 | 一种定向减毒的痘苗病毒疫苗 |
| CN116656730B (zh) * | 2023-05-25 | 2024-03-19 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法 |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| UA82466C2 (uk) | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
| CA2467365C (en) | 2001-12-10 | 2012-11-20 | Bavarian Nordic A/S | Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions |
| DK1646715T3 (da) | 2003-07-22 | 2010-08-16 | Vivalis | Fremstilling af poxvirum med adhærente eller ikke-adhærente fuglecellelinjer |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| GB0502661D0 (en) | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| KR101357685B1 (ko) | 2005-11-21 | 2014-02-06 | 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 | 재조합 바이러스용 안정화 제형 |
| PL1979474T3 (pl) | 2006-01-05 | 2011-01-31 | Transgene Sa | Ptasia odwrotna transkryptaza o charakterze telomerazy |
| DK2029756T3 (en) | 2006-06-20 | 2017-02-13 | Transgene Sa | PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS |
| CL2008000249A1 (es) | 2007-01-30 | 2008-05-30 | Transgene Sa | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| JP2010526546A (ja) | 2007-05-14 | 2010-08-05 | バヴァリアン・ノルディック・アクティーゼルスカブ | ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製 |
| TW200844230A (en) | 2007-05-15 | 2008-11-16 | Transgene Sa | Signaling peptides |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| JP5421250B2 (ja) | 2007-07-03 | 2014-02-19 | トランスジーン ソシエテ アノニム | トリ不死化細胞株 |
| HRP20150360T1 (hr) | 2007-11-19 | 2015-05-08 | Transgene Sa | Poksvirusni onkolitiäśki vektori |
| RU2503717C2 (ru) | 2007-11-19 | 2014-01-10 | Трансжене Са | Поксвирусные онколитические векторы |
| CN102257134B (zh) | 2008-02-12 | 2014-03-05 | 赛诺菲巴斯德有限公司 | 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法 |
| EP2199400A1 (en) | 2008-12-22 | 2010-06-23 | Emergent Product Development Germany GmbH | Single recombination system and methods of use |
| US8609392B2 (en) | 2009-05-12 | 2013-12-17 | Transgene S.A. | Method for orthopoxvirus production and purification |
| EP2569633B1 (en) * | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| EP2739293B1 (en) | 2011-08-05 | 2020-06-10 | SillaJen Biotherapeutics, Inc. | Methods and compositions for production of vaccina virus |
| WO2014012051A1 (en) * | 2012-07-12 | 2014-01-16 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| WO2014151117A1 (en) * | 2013-03-15 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and use of circulating nucleic acid tumor markers |
| EP2983702A2 (en) * | 2013-04-07 | 2016-02-17 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| US20160310584A1 (en) * | 2013-12-06 | 2016-10-27 | The Broad Institute Inc. | Formulations for neoplasia vaccines |
| KR102499737B1 (ko) | 2014-05-13 | 2023-02-13 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 재조합 폭스바이러스 및 면역 체크포인트 분자 길항제 또는 효현제로 암을 치료하기 위한 복합 요법 |
| ES2851451T3 (es) | 2014-05-13 | 2021-09-07 | Bavarian Nordic As | Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3 |
| IL294183B2 (en) | 2015-05-20 | 2023-10-01 | Dana Farber Cancer Inst Inc | shared neoantigens |
| MX2017015149A (es) | 2015-05-26 | 2018-03-28 | Advaxis Inc | Inmunoterapia personalizada basada en vectores de suministro y usos de esta. |
| TW202241500A (zh) * | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| WO2016207859A1 (en) | 2015-06-24 | 2016-12-29 | Advaxis, Inc. | Manufacturing device and process for personalized delivery vector-based immunotherapy |
| ES2970865T3 (es) * | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
| CA3056212A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene Corporation | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
-
2018
- 2018-06-21 WO PCT/EP2018/066668 patent/WO2018234506A2/en not_active Ceased
- 2018-06-21 JP JP2019570982A patent/JP7334124B2/ja active Active
- 2018-06-21 SG SG11201912429RA patent/SG11201912429RA/en unknown
- 2018-06-21 CA CA3067405A patent/CA3067405A1/en active Pending
- 2018-06-21 AU AU2018287159A patent/AU2018287159B2/en active Active
- 2018-06-21 KR KR1020247022788A patent/KR20240113607A/ko active Pending
- 2018-06-21 US US16/625,239 patent/US11969462B2/en active Active
- 2018-06-21 IL IL271558A patent/IL271558B2/en unknown
- 2018-06-21 KR KR1020207001211A patent/KR102684237B1/ko active Active
- 2018-06-21 EP EP18731146.9A patent/EP3641803A2/en active Pending
- 2018-06-21 CN CN201880050941.2A patent/CN111065406A/zh active Pending
-
2023
- 2023-04-13 US US18/299,858 patent/US20230277639A1/en active Pending
- 2023-06-19 JP JP2023100296A patent/JP2023123609A/ja active Pending
-
2025
- 2025-07-18 JP JP2025121773A patent/JP2025160281A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530437A5 (https=) | ||
| KR102021585B1 (ko) | 두 개의 벡터로부터 발현된 Cas9 단백질을 이용한 유전자 발현 조절 방법 | |
| Staib et al. | Transient host range selection for genetic engineering of modified vaccinia virus Ankara | |
| JP5474816B2 (ja) | ｍＲＮＡ翻訳エンハンサーエレメントに関する組成物および方法 | |
| CN108251452A (zh) | 一种表达Cas9基因的转基因斑马鱼及其构建方法和应用 | |
| CN113227387B (zh) | 基于单细胞转录组开发aav载体和启动子的方法和材料 | |
| CA2983364A1 (en) | Compositions and methods for the treatment of nucleotide repeat expansion disorders | |
| JP2018532419A (ja) | ＣＲＩＳＰＲ−Ｃａｓ ｓｇＲＮＡライブラリー | |
| US6395872B1 (en) | Secreted neural adhesion proteins | |
| JP2005522225A (ja) | 亢進された遺伝子発現系 | |
| CN117859703B (zh) | Anxa11基因的新突变致病位点C104G的敲入小鼠模型及其构建方法与应用 | |
| CN110885799A (zh) | 一种基于腺病毒的基因编辑方法 | |
| CN112899237A (zh) | Cdkn1a基因报告细胞系及其构建方法和应用 | |
| US9765305B2 (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
| KR101613457B1 (ko) | 고추 식물 유래 신규한 고추 난쟁이 엔도르나바이러스 유전자 | |
| KR940001265B1 (ko) | 프로모터, 그를 함유하는 플라스미드 및 재조합 아비폭스비루스 | |
| US6841347B1 (en) | In vivo construction of DNA libraries | |
| KR102955030B1 (ko) | 신규한 가이드 rna 및 이의 용도 | |
| CN119506355B (zh) | 一种用于重组痘病毒包装的载体系统及其应用 | |
| JP7034818B2 (ja) | 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法 | |
| CN109868288A (zh) | 用于果蝇CRISPR转基因的cas9转录模板DNA及质粒DNA和体外转录方法 | |
| WO2009144958A1 (ja) | 組換えウイルス、これを保持する大腸菌およびその製造法 | |
| RU2020101489A (ru) | Персонализированная вакцина | |
| JP4216875B2 (ja) | メタノール応答性プロモーター、プロモーターと外来遺伝子を発現可能な様式で連結した融合遺伝子、ベクター、形質転換体、およびタンパク質の生産方法 | |
| CN121204055A (zh) | 一种靶向敲除猪pLEG1c基因座的方法 |